MedPath

THE UNIVERSITY OF HONG KONG

🇭🇰Hong Kong, China
Ownership
-
Employees
-
Market Cap
-
Website

Brief Advice, Nicotine Replacement Therapy Sampling and Active Referral (BANSAR) for Smoking Fathers

Not Applicable
Completed
Conditions
Tobacco Use Cessation
Smoking Cessation
Interventions
Behavioral: Very brief advice
Behavioral: Brief AWARD advice
Drug: Nicotine replacement therapy sampling
Behavioral: Leaflet
Behavioral: Active referral
First Posted Date
2018-09-14
Last Posted Date
2021-08-17
Lead Sponsor
The University of Hong Kong
Target Recruit Count
1053
Registration Number
NCT03671707
Locations
🇭🇰

School of Nursing, The University of Hong Kong, Hong Kong, Hong Kong

Use of Diathermy Versus Blunt Dissection in TEP for Inguinal Hernia

Not Applicable
Completed
Conditions
Seroma
Hernia, Inguinal
Interventions
Procedure: Blunt dissection
Procedure: Monopolar energy
First Posted Date
2018-09-11
Last Posted Date
2020-03-25
Lead Sponsor
The University of Hong Kong
Target Recruit Count
103
Registration Number
NCT03665883
Locations
🇨🇳

Department of Surgery, The University of Hong Kong - Shenzhen Hospital, Shenzhen, Guangdong, China

Outcomes of Restoring Untreated and SDF-treated Dentine Caries Lesions in Primary Teeth of Preschool Children

Not Applicable
Conditions
Dental Restoration Failure of Marginal Integrity
Interventions
Device: application of 38% silver diamine fluoride solution
Other: application of a placebo (tonic water)
First Posted Date
2018-09-05
Last Posted Date
2018-09-05
Lead Sponsor
The University of Hong Kong
Target Recruit Count
195
Registration Number
NCT03657862
Locations
🇨🇳

The University of Hong Kong, Hong Kong, China

Effectiveness on SDF Solution and PVP-I Combined NaF Varnish in Preventing Root Caries in Elders

Not Applicable
Conditions
Root Caries
Interventions
Device: SDF solution
Device: PVP-I solution combined with NaF varnish
First Posted Date
2018-08-31
Last Posted Date
2018-09-05
Lead Sponsor
The University of Hong Kong
Target Recruit Count
353
Registration Number
NCT03654820
Locations
🇨🇳

The University of Hong Kong, Hong Kong, China

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Phase 2
Conditions
EGFR Activating Mutation
NSCLC Stage IV
NSCLC Stage IIIB
Interventions
First Posted Date
2018-08-27
Last Posted Date
2019-04-17
Lead Sponsor
The University of Hong Kong
Target Recruit Count
40
Registration Number
NCT03647956
Locations
🇭🇰

Department of Clinical Oncology, Hong Kong, Hong Kong

Exploring the Mental Health of Parents Having Children With Cancer

Completed
Conditions
Resilience of Parents Having Children With Cancer
Interventions
Other: Exposure_having children with cancer
First Posted Date
2018-08-15
Last Posted Date
2019-05-30
Lead Sponsor
The University of Hong Kong
Target Recruit Count
181
Registration Number
NCT03631485
Locations
🇭🇰

The University of Hong Kong, Hong Kong, Hong Kong

The Hong Kong CML Registry

Conditions
Chronic Myeloid Leukemia
First Posted Date
2018-08-10
Last Posted Date
2018-08-10
Lead Sponsor
The University of Hong Kong
Target Recruit Count
200
Registration Number
NCT03625583
Locations
🇭🇰

The University of Hong Kong, Hong Kong, Hong Kong

Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia

Phase 2
Recruiting
Conditions
Acute Promyelocytic Leukemia
Interventions
Drug: Oral arsenic Trioxide, ATRA and ascorbic acid
First Posted Date
2018-08-10
Last Posted Date
2022-10-04
Lead Sponsor
The University of Hong Kong
Target Recruit Count
60
Registration Number
NCT03624270
Locations
🇭🇰

Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, N/A = Not Applicable, Hong Kong

SIMPLE Chemotherapy for NK Lymphoma/Leukaemia

Phase 3
Conditions
Non-Hodgkin's Lymphoma, Relapsed
Non-Hodgkin T-cell Lymphoma
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Interventions
First Posted Date
2018-08-09
Last Posted Date
2018-08-14
Lead Sponsor
The University of Hong Kong
Target Recruit Count
68
Registration Number
NCT03623087
Locations
🇭🇰

The University of Hong Kong, Hong Kong, Hong Kong

Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

Phase 2
Completed
Conditions
FLT3-ITD Mutation
AML
Interventions
First Posted Date
2018-08-09
Last Posted Date
2020-03-30
Lead Sponsor
The University of Hong Kong
Target Recruit Count
46
Registration Number
NCT03622541
Locations
🇭🇰

The University of Hong Kong, Hong Kong, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath